Pfizer Trades at Sub-9 P/E with 6.7% Yield Despite Patent Cliffs
Pfizer’s stock trades at a forward P/E under 9 and offers a 6.7% dividend yield while facing upcoming patent expirations on key drugs like Eliquis, Vyndaqel, Ibrance and Xtandi. Strategic acquisitions of Seagen in 2023 and Metsera aim to bolster its pipeline despite revenue headwinds.
Related News
WPM
Wheaton Precious Metals Publishes Report Highlighting $9.4M Community Investment and MSCI AAA Rating
WPM•
CRM
Salesforce Faces Competition from Nvidia’s $200B AI CPU, Nasdaq Rally
CRM•
JPM
J.P. Morgan Joins SpaceX $1.75 Trillion Nasdaq IPO With $1.45B Bitcoin Disclosure
JPM•
BA
NTSB: Boeing Extended MD-11 Inspection Interval 47% Before Deadly UPS Crash
BA•
NVDA
Nvidia Raises July Quarter Guidance, Forecasts $91B Fiscal 2027 Revenue
NVDA•
Sources
FGBGG